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Abstract
Objective. The purpose of this study is to assess
Florida physicians’ attitudes and knowledge toward
accessing the state’s prescription drug monitoring
program (PDMP).
Design. Five thousand medical doctors and osteo-
pathic physicians licensed in Florida were randomly
selected for a voluntary and anonymous 15-
question self-administered survey approved by the
Institutional Review Board. Surveys were distrib-
uted through U.S. postal service mail. Likert-scale
questions were used to assess prior knowledge
(15none to 55excellent) and attitudes toward
accessing the PDMP (15 strongly disagree to
55 strongly agree).
Results. The study yielded a response rate of 7.8%,
71.5% of whom agreed or strongly agreed that the
PDMP is a useful tool. Among participants that have
access and answered the PDMP usefulness ques-
tion, 94.8% agree or strongly agree that it is a useful
tool. There were 63 out of 64 physicians (98.4%) who
conducted 25 or more searches who agreed or
strongly agreed that the PDMP is a useful tool for
monitoring patients’ controlled substance histories.
There were 72.5% of participants with access that
answered the “doctor shopping” question who
agreed that “doctor shopping” will decrease. Among
the 64 most frequent PDMP users, 69.4% agreed or
strongly agreed that they have prescribed fewer
controlled substances after accessing the PDMP.
Conclusions. The study revealed that a majority of
participants believe that the PDMP is a useful tool
for monitoring patients’ controlled substance his-
tories. More continuing education programs should
be provided to Florida physicians to enhance their
knowledge regarding PDMPs.
Key Words. Controlled Substances; Electronic-
Florida Online Reporting Controlled Substance
Evaluation; Physicians; Prescription Drug Monitor-
ing Programs
Introduction
As of November 1, 2013, 49 states and two U.S. Territo-
ries have enacted legislation establishing a prescription
drug monitoring program (PDMP) [1]. The Obama Admin-
istration issued the 2013 Prescription Drug Abuse Preven-
tion Plan, and one of the four major focuses is tracking
and monitoring controlled substances through PDMPs [2].
According to the Centers for Disease Control and Preven-
tion, approximately 15,000 individuals die annually from
prescription overdoses involving opioid analgesics [3].
Approximately 48,000 women died of opioid overdoses
between 1999 and 2010 [4]. Prescription drug abuse in
2013
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Florida has historically been a major public health threat,
as six individuals die every day from overdoses as of Sep-
tember 2013 [5]. In 2009, there were more pain clinics
than McDonald’s restaurants in Broward County, Florida
[6]. The growth of “pill mills” or facilities conducting unlaw-
ful prescribing and dispensing of controlled substances
outside the standards of medical practice, is an important
driving force in the prescription drug abuse epidemic [6].
Weak regulations and poor oversight of pain clinics, limited
oversight of physician dispensing, and Florida’s failure to
react soon to implement stricter laws were crucial factors
involved in the epidemic [6]. According to the 2012 Florida
Medical Examiner’s Report, deaths caused by oxycodone
decreased by 41.1% [5]. However, deaths caused by her-
oin increased by 89.5% compared with 2011 [5]. The
reduction in oxycodone deaths may be the result of the
PDMP and stricter pain clinic laws and regulations [7].
Florida’s PDMP is known as the Electronic-Florida Online
Reporting Controlled Substance Evaluation, which is an
electronic database that collects and stores controlled
substance dispensing information for schedules II–IV [8].
Pharmacies began submitting controlled substance data
effective September 1, 2011 [8]. All controlled substance
data must be submitted to the Florida Department of
Health within 7 days of dispensing [8]. House Bill 7095
established that physicians are prohibited from dispensing
schedules II and III medications [9]. Therefore, data sub-
mission mostly applies to pharmacies. Florida’s PDMP
became operational September 1, 2011, meaning that
health care practitioners could begin accessing patient
advisory reports (PAR); however, they are not required by
law to do so [9]. The PAR is a summary of patients’ con-
trolled substance histories as specified by the health care
practitioner’s query [9]. Physicians can request access to
Florida’s PDMP by completing a request form with their
name, date of birth, last four digits of their social security
number, state license number and license type, DEA num-
ber, and contact information [10]. As of October 31, 2013,
11% of licensed medical doctors and 24.3% of osteo-
pathic licensed physicians are registered to access the
PDMP [11]. Of those individuals registered, 69.7% of med-
ical doctors and 77.7% of osteopathic physicians have
made requests through the PDMP [11].
The purpose of this study was to evaluate Florida physi-
cians’ attitudes and knowledge toward accessing the
state’s PDMP.
Methods
Five thousand medical doctors and osteopathic physi-
cians licensed in Florida as “active” status and a license
status description as clear (licensed physician is clear to
practice in Florida) with Florida addresses were ran-
domly selected from more than 58,413 medical doctors
(MDs) and 5,810 osteopathic physicians (DOs) listed in
the Florida Licensee Data Center within the Department
of Health. This study was approved by the Institutional
Review Board of Nova Southeastern University. MDs
and DOs herein identified as “physicians” were random-
ized together to identify a sample representative of the
true population. Physicians’ mailing addresses, names,
and licensure information were utilized strictly for study
purposes and were not linked back to any participants.
No financial or other incentives were provided to the
study respondents. The study was a voluntary and
anonymous 15-question self-administered survey
accompanied by a cover letter with a description of
Florida’s PDMP and information regarding physician
access to the database. The investigators downloaded
the physician information from the Licensee Data Center
into a Microsoft Excel spreadsheet. Surveys were dis-
tributed through U.S. postal service mail, and the study
was conducted from January 2013 to June 2013. All
participants received a reminder postcard through the
U.S. mail approximately 1 week after receipt of the sur-
vey. Participants were provided with a postage-paid
envelope to increase the response rate. The survey
included demographic questions regarding practice sta-
tus, such as the number of years licensed as a physi-
cian and primary area of practice. Likert-scale questions
were used to assess prior knowledge (from 15 none to
55 excellent) and attitudes toward accessing the PDMP
(from 15 strongly disagree to 55 strongly agree). Study
participants were questioned regarding PDMP access
including rationale for applying/not applying to the pro-
gram. The last question enabled study participants to
provide comments and discuss issues not mentioned in
the survey. Data were analyzed using SPSS software
(Statistics for Windows, Version 21.0, IBM Corporation.
Armonk, NY, USA), and both descriptive and inferential
statistics were included in the results.
Results
A total of 388 surveys were completed, and 37 were
returned as undeliverable. The calculated response rate
was 7.8% for all surveys mailed.
The PDMP’s Utility for Monitoring Patients’ Controlled
Substance Histories
A total of 256 out of 358 participants or 71.5% agreed or
strongly agreed that the PDMP is a useful tool. Among
the 89 individuals who answered the question with neither
agree nor disagree, four participants had access to the
PDMP. The additional 85 had not applied for access.
There were 63 of 64 physicians (98.4%) who conducted
25 or more searches who agreed or strongly agreed that
the PDMP is a useful tool for monitoring patients’ con-
trolled substance histories. Among participants that had
access and answered the PDMP usefulness question-
naire, 128/135 physicians (94.8%) agreed or strongly
agreed that it is a useful tool (Table 1). Additionally, indi-
viduals without access who answered the usefulness
question (122/215 physicians, 56.7%) indicated that the
PDMP was a useful tool. Additionally, of the 110 physi-
cians who have not applied for access and listed their
level of PDMP knowledge as none, 2.7% (3/110 respond-
ing to the usefulness question) responded that they dis-
agreed or strongly disagreed that the PDMP is a useful
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tool. There were 43.6% of the 110 physicians who agreed
or strongly agreed that the PDMP is a useful tool.
Among the 254 individuals answering the years licensed
and practice question that agreed or strongly agreed
that the PDMP is useful, their mean was 23.6 years of
practice. Among the 12 participants answering the years
licensed and practice question that disagreed or
strongly disagreed that the PDMP was useful, they aver-
aged 28.3 years of practice.
Those who practice longer tended to find the PDMP
less useful.
PDMP Utility by Specialty
Physician specialists that agreed or strongly agreed the
PDMP was a useful tool were Emergency Medicine (95%),
Ophthalmology (85.7%), Orthopedics (85.7%), Internal
Medicine (84.6%), Psychiatry (84%), Neurology (83.3%),
Obstetrician/Gynecologist (OB/GYN) (81.3%), and Family
Practice (76.3%). Specialties with the least individuals
responding agreed or strongly agreed were Dermatology
(20%), Infectious Disease (0%), and Urology (0%) (Table 2).
Doctor Shopping
Among participants without access and that responded
to the “doctor shopping” question, 53.9% of them
agreed or strongly agreed that “doctor shopping” will
decrease. Additionally, 72.5% (98/135) who had access
and answered the “doctor shopping” question agreed
that “doctor shopping” will decrease (Table 1). Approxi-
mately 9.2% (33/358) of participants feel that the PDMP
will not decrease “doctor shopping.”
Doctor Shopping Attitudes by Specialty
The specialties with the most participants that agreed or
strongly agreed that the PDMP would decrease “doctor
shopping” were Ophthalmology (85.7%), Pain Manage-
ment (81.8%), Psychiatry (79%), Infectious Disease
(75%), Physiatrist (75%), and Emergency Medicine (70%).
Also, the areas of practice with the least individuals
responding agreed or strongly agreed were Pediatrics
(46.9%), Dermatology (20%), and Urology (0%) (Table 3).
Controlled Substance Prescribing Practices
Approximately 3.7% of participants disagreed or
strongly disagreed with the statement that their con-
trolled substance prescribing practices are being moni-
tored more closely since Florida’s PDMP was
implemented. There were 82 physicians who responded
that they agreed or strongly agreed that they have pre-
scribed fewer controlled substances after accessing the
PDMP, and among these 82.9% (68/82) also agreed or
strongly agreed that they believe their controlled sub-
stance prescribing practices are being monitored more
closely since Florida’s PDMP was implemented. The
question regarding prescribing fewer controlled substan-
ces was analyzed. A total of 74 physicians disagreed or
strongly disagreed that they have prescribed fewer con-
trolled substances, and 56.7% (47/74) of these partici-
pants agreed or strongly agreed that their controlled
substance prescribing practices are being monitored
more closely. Among the 64 most frequent PDMP users
(accessed at least 25 patients), 69.4% (43/62) that
responded to the question agreed or strongly agreed
that they have prescribed fewer controlled substances
after accessing the PDMP. A total of 64 individuals
responded that they have completed more than 25
searches in the PDMP. Only 62 answered the question
regarding prescribing fewer controlled substances.
Table 1 Participant distribution for PDMP usefulness and doctor shopping
Have Access In Progress
Do Not Have
Access
Useful (agree or strongly agree) 128 out of 135 5 out of 7 122 out of 215
Doctor shopping decreases (agree or strongly agree) 98 out of 135 3 out of 7 116 out of 215
PDMP5 prescription drug monitoring program.
Table 2 PDMP is a useful tool by specialty
(agree or strongly agree)
Specialty Percentage
Anesthesiology 60
Cardiology 57.1
Dermatology 20
Emergency medicine 95
Family practice 76.3
Infectious disease 0
Internal medicine 84.6
Neurology 83.3
OB/GYN 81.3
Ophthalmology 85.7
Orthopedics 85.7
Pain management 81.8
Pediatrics 56.3
Physiatrist 62.5
Plastic surgeon 66.7
Psychiatry 84
Urology 0
PDMP5 prescription drug monitoring program.
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Impact on Pain Management
Out of the nine physicians that listed pain management
as their primary practice area and responded to the
statement that “the PDMP has had a negative impact
on pain management in my practice,” 12.5% (1/8)
agreed or strongly agreed with the statement.
Knowledge and by Specialty
Among the 89 individuals that neither agreed nor dis-
agreed with the statement that the PDMP is a useful
tool for monitoring patients’ controlled substance histor-
ies, nine participants felt that their knowledge was good
or very good. Also, lack of knowledge was the most
common response for why the participants do not seek
access to the PDMP. The specialties with the most
physicians who rated their knowledge as good, very
good, or excellent were Emergency Medicine (82.5%)
and Pain Management (81.8%). The areas of practice
with 0% of individuals rating their knowledge as good,
very good, or excellent were Infectious Disease and
Orthopedics (Table 4).
Access and by Specialty
Among the 89 individuals that neither agreed nor dis-
agreed that the PDMP is a useful tool, four participants
have access. The other 85 participants have not applied
for access. The specialties with the most physicians
with PDMP access are Pain Management (90.9%) and
Emergency Medicine (77.5%). Specialties with 0% of
individuals with access include Cardiology, Dermatology,
Infectious Disease, Ophthalmology, and Urology
(Table 5).
Discussion
Studies evaluating physician use and attitudes of
PDMPs are limited [12–17]. Clearly, physician PDMP
studies demonstrate a need for prescriber education.
Feldman et al. evaluated PDMP usage in an academic
Table 4 Knowledge of PDMP by specialty
(responding good, very good, or excellent)
Specialty Knowledge %
Anesthesiology 7.7
Cardiology 0
Dermatology 20
Emergency medicine 82.5
Family practice 52.5
Infectious disease 0
Internal medicine 49
Neurology 57.1
OB/GYN 11.1
Ophthalmology 28.6
Orthopedics 0
Pain management 81.8
Pediatrics 16.7
Physiatrist 50
Plastic surgeon 33.3
Psychiatry 47.4
Urology 50
Table 3 “Doctor shopping” will decrease by
specialty (agree or strongly agree)
Specialty Percentage
Anesthesiology 50
Cardiology 57.1
Dermatology 20
Emergency medicine 70
Family practice 57.6
Infectious disease 75
Internal medicine 66
Neurology 66.7
OB/GYN 50
Ophthalmology 85.7
Orthopedics 57.1
Pain management 81.8
Pediatrics 46.9
Physiatrist 75
Plastic surgeon 66.7
Psychiatry 79
Urology 0
Table 5 PDMP access by specialty
Specialty
Access/Applied for
Access %
Anesthesiology 7.7% have access
Cardiology 0% have access
Dermatology 0% have access
Emergency medicine
77.5% have access/1 individual
applied for access
Family practice
52.5% have access/2 individuals
have applied for access
Infectious disease 0% have access
Internal medicine
49.1% have access/3 individuals
have applied for access
Neurology 14.3% have access
OB/GYN 11.1% have access
Ophthalmology 0% have access
Orthopedics 25% have access
Pain management 90.9% have access
Pediatrics 11.1% have access
Physiatrist 50% have access
Plastic surgeon 33.3% have access
Psychiatry 47.4% have access
Urology 0% have access
PDMP5 prescription drug monitoring program.
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medical setting and whether the program influenced
prescribing behavior [12]. The voluntary and anonymous
survey included questions regarding demographic data,
awareness of the PDMP, reasons for accessing the sys-
tem, and prescribing practice influences. The survey was
distributed to 156 practicing physicians in the emergency
medicine, internal medicine, neurology, pediatrics, and
psychiatry departments in Ohio. The survey response rate
was 61%, and 84% of participants were aware of Ohio’s
PDMP. Of the physicians aware of the PDMP, 58.8%
reported utilizing the database. All physicians who were
unaware of the state PDMP reported that they would uti-
lize the program if they knew of its existence. Additionally,
over 91% of physicians reported concern regarding pre-
scription drug abuse as the top reason for accessing the
database. Also, 93.6% of physicians accessing the
PDMP reported that utilization influenced the type and
quantity of medication prescribed. Approximately 68% of
physicians reported switching the medication to a non-
scheduled drug. Also, 30% of individuals were less con-
cerned regarding prescribing controlled substances after
accessing the PDMP [12]. Additionally, Feldman et al.
evaluated the influence of attending physician awareness
and utilization of a state prescription monitoring program
on resident physician behavior [13]. Twenty-five attending
physicians and 70 residents completed a survey regard-
ing awareness and utilization of a state prescription moni-
toring program. The study found that residents were
significantly more likely to use the system through the
influence of supervising physicians [13].
Baehren et al. conducted a prospective study to evaluate
the influence of the PDMP data on clinical management of
emergency department patients with pain, and to identify
factors associated with therapy changes in Toledo, Ohio
[14]. The inclusion criteria specified patients 18 years and
older with a chief complaint of painful conditions, and the
participants were obtained as a convenience sample. The
physicians were questioned regarding the likelihood of
querying the PDMP databases for each patient and the
probability of prescribing a controlled substance including
which medication and quantity. Then the PDMP data were
presented to the physician who then received the same
questions to determine any changes in behavior. A total of
199 individuals were enrolled, and 179 patients completed
the study. Prior to accessing the PDMP, physicians indi-
cated a high likelihood (32%), moderate likelihood (26%),
and low likelihood (36%) that controlled substances would
be prescribed. The PDMP data demonstrated that there
was an average of 18.9 prescription narcotics per patient
over a 12-month period. After physicians reviewed the
PDMP, opioid prescribing was changed for 41% of
patients, with 61% of these resulting in fewer or no opioids
compared with the presurvey. Additionally, 39% of
patients were prescribed more pain medications than orig-
inally planned after reviewing the PDMP data [14].
Barrett et al. evaluated physicians’ knowledge and atti-
tudes toward the Virginia pilot PDMP for schedule II
controlled substances and its impact on opioid prescrib-
ing behaviors [15]. A total of 672 physicians were
selected for the survey, and the response rate was
41%. Forty-eight percent of physicians had knowledge
of the PDMP prior to receiving the survey. Of the study
participants with prior knowledge of the PDMP, 40%
were classified as family practice physicians, and 31%
were categorized as internal medicine. Physicians had
an average of 20 years of practice experience. Only
11% of physicians reported that they requested informa-
tion about a patient’s prescription record. Individuals
that had not accessed the PDMP described reasons
including a lack of knowledge regarding the ability to
request information (40%), information not viewed as
necessary (25%), and data not being available immedi-
ately (18%). Additionally, 60% of physicians believed
that their prescribing practices were being monitored
more closely as a result of the PDMP. Sixty-eight per-
cent of physicians believed that the PDMP was useful
for monitoring patients’ schedule II prescription records
including decreasing the incidence of doctor shopping
with a significant association (P<0.001) [15].
Perrone et al. evaluated the opinions of medical toxicolo-
gists toward opioid prescribing and their knowledge and
use of PDMPs [16]. Also, opinions of their state’s PDMP
limitations were assessed. Surveys were sent to 445
individuals nationally, and the overall response rate was
46%. A majority of the respondents (78%) practice
emergency medicine. The study found that 27.3% of
participants reported in-depth knowledge regarding
PDMPs, and a majority (87.2%) had at least some
knowledge. More than 25% of participants did not
access their state’s PDMP because they were either not
knowledgeable about the availability of the program in
their state (13.5%) or not registered for access (12.4%).
There were 50.6% of all respondents that have used
their state’s PDMP, with 30% of those accessing it
daily, 47% weekly, and 23% monthly [16].
Weiner et al. compared emergency clinician impressions
of drug-seeking behavior based on clinical evaluation with
objective data from the Massachusetts PDMP through a
two-site prospective, observational study [17]. Addition-
ally, the study evaluated whether PDMP data changed
prescribing behavior. Thirty-eight emergency providers
with PDMP access participated in the study, with 544
patient encounters included. There was only fair agree-
ment between emergency provider impressions and
PDMP data. After reviewing PDMP data, emergency pro-
viders changed plans to prescribe opioids at discharge in
9.5% of cases (95% CI 7.3% to 12.2%), with 6.5% of
patients receiving opioids not previously prescribed and
3% no longer receiving opioids [17].
This is the first published study to assess Florida physi-
cians’ knowledge and attitudes toward accessing the
state prescription drug monitoring program. Additionally,
this study surveyed a larger sample size than previous
studies and unlike the others, did not limit the physician
practice setting. There were 71.5% of participants that
agreed or strongly agreed that the PDMP is a useful
tool for monitoring patients’ controlled substance
Prescription Drug Monitoring Program
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histories. All previously published studies also demon-
strated that physicians believe PDMPs are useful tools.
Of individuals conducting 25 or more searches via the
PDMP, all believed it is a useful tool. Therefore, as indi-
viduals utilize the PDMP, they are more likely to believe
in the PDMP’s utility. There is high correlation between
physicians that have good knowledge of the PDMP and
those that have chosen to access the data. Therefore,
this study has revealed that physician education regard-
ing the PDMP increases utility and may have a positive
outcome in terms of reducing access to prescription
opioids and other controlled substances when in cases
where multiple prescribers are sought. Physicians with
access to the PDMP are more likely to feel that it will
prevent “doctor shopping” than those who do not have
access. This may be a result of what they see in prac-
tice. Also, a belief of being more closely monitored was
associated with a decrease in controlled substance pre-
scribing. Physicians utilizing the PDMP more frequently
may have a positive impact since they are prescribing
fewer controlled substances. This study did not evaluate
whether a negative impact exists for legitimate patients
due to physicians’ fears of being more highly scrutinized
and monitored by regulatory agencies. This is an impor-
tant factor because as clinicians it is important to man-
age patients’ pain while preventing prescription drug
abuse [18]. Future studies may include targeting specific
physician specialties, such as pain management, as the
PDMP largely impacts these individuals. Only 11 pain
management physicians responded to the PDMP use-
fulness question; therefore, the sample size was small.
Emergency Medicine physicians should also be targeted
as this study revealed that a majority of this specialty
are knowledgeable of the PDMP and have access to
the program. Previous studies have also demonstrated
that Emergency Medicine physicians utilize the PDMP,
although some states such as New York, Kentucky,
and Tennessee, which otherwise require a database
inquiry by prescribers, dismiss this obligation if the
quantity is limited to a predetermined short supply by
days or unit number [19]. The study revealed unex-
pected results for Infectious Disease physicians, as 0%
agreed or strongly agreed that the PDMP was a useful
tool. However, 75% thought it would decrease “doctor
shopping.” This may be indicative that in general they
do not prescribe controlled substances and the PDMP
is therefore not useful for their specialty. However, Infec-
tious Disease doctors are presumably in a unique posi-
tion to prescribe controlled substances for a patient
population with very high substance abuse prevalence
when one considers the cohort of patients with human
immunodeficiency virus and/or hepatitis C virus [20].
This ominous finding may warrant further scrutiny. This
study had limitations, such as the small response rate
(7.8%), which may limit the generalizability of the study.
The low response rate may be the result of surveying a
number of physician specialists not impacted by the
PDMP, especially as presumably they may prescribe
few controlled substances with any regularity. The study
found that individuals practicing longer tend to find the
PDMP less useful. This may indicate that older physi-
cians may be less savvy with technology, which can be
further evaluated in a follow-up study. Florida pharma-
cists should also be evaluated to assess their use and
opinions of the PDMP.
Conclusion
The study revealed that a majority of participants believe
that the PDMP is a useful tool for monitoring patients’
controlled substance use, history of that use, and poten-
tial “doctor shopping.” This study surveyed the largest
amount of physicians compared with other similar studies
from other state PDMPs regarding prescriber attitudes
and knowledge toward accessing the Florida PDMP.
Although the overall impact seems to have decreased
controlled substance prescriptions, we do not know if
there is a negative impact to legitimate pain patients in the
state of Florida. Future studies should target specific spe-
cialties in Florida and also assess the overall positive and
negative impact to legitimate pain patients as well as
“doctor shoppers.” Additionally, more continuing educa-
tion programs should be provided to Florida physicians to
enhance their knowledge regarding PDMPs.
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